There are currently 93 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
NCT04368039
Recruiting
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Gender:
ALL
Ages:
Between 15 years and 35 years
Trial Updated:
10/28/2024
Locations: Harding Hospital, Columbus, Ohio
Conditions: Psychosis, Schizophrenia, First-episode Psychosis
Register for Updates
CAE for Poorly Adherent Individuals with Schizophrenia
NCT06061952
Recruiting
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Schizophrenia
Register for Updates
Alexithymia Intervention for Suicide
NCT05724953
Recruiting
Suicide rates among Veterans with Serious Mental Illness (SMI) are intractably high, representing a serious public health concern and a critical target for interventions. Yet, at present available treatments offer modest benefits. Thus, there remains an urgent need to identify novel approaches to address suicide risk in this population. Previous reports have linked suicide risk with poor social functioning. Emerging evidence from basic affective neuroscience research has indicated that effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York
Conditions: Suicide, Schizophrenia, Bipolar Disorder, Post Traumatic Stress Disorder, Major Depressive Disorder
Register for Updates
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
04/02/2025
Locations: Alkermes Investigator Site, Dothan, Alabama +43 locations
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
Acetazolamide for Treatment Resistant Schizophrenia
NCT04887792
Recruiting
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/02/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania +1 locations
Conditions: Schizophrenia, Schizo Affective Disorder
Register for Updates
Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia
NCT04267003
Recruiting
People with schizophrenia often have problems with attention, learning and memory and other cognitive abilities that interfere with their work and school performance. Unfortunately, even our best treatments often do not significantly reduce these cognitive problems. The current study investigates whether or not delivering a very small electrical current to people's foreheads (called, transcranial direct current stimulation; (tDCS)) might improve functioning in the front part of the brain and red... Read More
Gender:
ALL
Ages:
Between 18 years and 47 years
Trial Updated:
04/01/2025
Locations: Imaging Research Center, Sacramento, California
Conditions: Schizophrenia
Register for Updates
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
NCT00001246
Recruiting
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution. Functional MRIs are diagnostic tests that allow doctors to not only view anatomy, but physiology and function. It is for these reasons that MRIs are excellent methods for studying the brain. In this study, researchers will use MRI to assess brain anatomy and function in X and Y chromosome variation... Read More
Gender:
ALL
Ages:
Between 3 years and 120 years
Trial Updated:
04/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder
Register for Updates
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
NCT05838560
Recruiting
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/27/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Schizophrenia, Treatment Resistant Depression, Aging, Premature
Register for Updates
Study of SPG302 in Adults With Schizophrenia
NCT06442462
Recruiting
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/27/2025
Locations: CenExel CNS, Garden Grove, California +2 locations
Conditions: Schizophrenia
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2025
Locations: Alea Research, Phoenix, Arizona +172 locations
Conditions: Schizophrenia
Register for Updates
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964
Recruiting
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
03/26/2025
Locations: Site 5038, Garden Grove, California +5 locations
Conditions: Schizophrenia, Cognitive Impairment
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: North County Clinical Research, Oceanside, California +11 locations
Conditions: Schizophrenia
Register for Updates